LY329201

Subscribe to Selected New Research on LY329201

2 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Also Known As:

(R)-N-((5-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)-2-thienyl)carbonyl)-L-glutamatic acid disodium salt

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Amino Acids: 8523

Excitatory Amino Acids: 1084

Glutamic Acid: 7419

LY329201: 2

Acidic Amino Acids: 33

Glutamic Acid: 7419

LY329201: 2

Dicarboxylic Amino Acids: 20

Glutamic Acid: 7419

LY329201: 2

Related Diseases

1.	Experimental Arthritis 07/01/2005 - "LY329201 as well as methotrexate demonstrated a dose dependent reduction in both paw and spleen weight and improved joint histology following 2 weeks of dosing in a rat adjuvant arthritis study" Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 04/01/1999 - "While an additive tumor response was observed when MTA was administered with methotrexate, synergistic tumor responses were seen when MTA was administered with the GARFT inhibitor, LY329201, or with the topoisomerase I inhibitor, irinotecan" Get all the results and reference details, order at left...
3.	Carcinoma (Carcinomatosis) 04/01/1999 - "LY231514, a multitargeted antifolate (MTA), was tested in combination with cisplatin, methotrexate, 5-fluorouracil, paclitaxel, docetaxel, doxorubicin, LY329201 (a glycinamide ribonucleotide formyltransferase [GARFT] inhibitor), and fractionated radiation therapy in vivo using EMT-6 mammary carcinoma, human HCT 116 colon carcinoma, and human H460 nonsmall cell lung carcinoma grown as xenografts in nude mice" Get all the results and reference details, order at left...
4.	Breast Neoplasms (Breast Cancer) 04/01/1999 - "LY231514, a multitargeted antifolate (MTA), was tested in combination with cisplatin, methotrexate, 5-fluorouracil, paclitaxel, docetaxel, doxorubicin, LY329201 (a glycinamide ribonucleotide formyltransferase [GARFT] inhibitor), and fractionated radiation therapy in vivo using EMT-6 mammary carcinoma, human HCT 116 colon carcinoma, and human H460 nonsmall cell lung carcinoma grown as xenografts in nude mice" Get all the results and reference details, order at left...
4 Diseases and 2 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Methotrexate (Mexate)
2.	Paclitaxel (Taxol)
3.	Fluorouracil (Carac)
4.	Doxorubicin (Adriamycin)
5.	Type I DNA Topoisomerases (Topoisomerase I)
6.	Cisplatin (Platino)
7.	glycinamide ribonucleotide
8.	pemetrexed (MTA)
9.	docetaxel (Taxotere)
10.	irinotecan (Camptosar)
10 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>